Siemens Regulatory Approval

Siemens Q2 FY27 Results: Net Profit ₹504.2 Cr, Up 3.9% YoY

Siemens Ltd reported revenue from operations of ₹5,734 Cr (+17.0% YoY) and net profit of ₹504.2 Cr (+3.9% YoY) for Q2 FY27.

Key figure

Net profit ₹504.2 Cr · +3.9% YoY

Siemens Board Meeting Date

Siemens Limited informed exchanges that its Board will meet on 6 November 2026 to consider unaudited results for the quarter and half-year ended 30 September 2026. The filing is advance notice only.

Siemens Capital Structure Change

Siemens Ltd's subsidiary C&S Electric completed a capital reduction, cancelling 343,948 minority shares for Rs 34.95 Crore. C&S is now a wholly owned subsidiary of Siemens.

Value

₹34.95 Cr

Siemens Other Announcement

Siemens Ltd has filed its quarterly shareholding pattern as mandated by SEBI regulations. This routine disclosure details the company's shareholding structure for the quarter ended September 2026.

Siemens Management Change

Siemens Limited announced the cessation of Mr. Matthias Rebellius as Special Director and the appointment of Ms. Veronika Bienert as his successor, effective October 2026.

Siemens Other Announcement

Siemens informed shareholders to update their KYC details with the Registrar and Share Transfer Agent as mandated by SEBI.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.